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EvidEncE-basEd answEr
A 	
	 What	therapies	alleviate	
symptoms	of	polycystic	ovary	
syndrome?
	 Treatment of polycystic ovary
 syndrome (PCOS)	 in	 women	
not	 actively	 seeking	 to	 become	 pregnant	
is	 symptom-specific.	 Lifestyle	 modifica-
tion	(LSM)	reduces	body	weight	by	3.5	kg	
(strength	 of	 recommendation	 [SOR]:	 A,	
meta-analysis)	 and	 metformin	 reduces	 it	
by	3	kg	(SOR	B,	cohort	trial).	
LSM	 may	 be	 better	 tolerated;	 add-
ing	metformin	to	LSM	doesn’t	 lead	to	ad-
ditional	weight	 loss	 (SOR:	B, randomized	
controlled	trial	[RCT]).	
Spironolactone	 improves	 hirsutism	
scores	 by	 an	 absolute	 8%	 to	 22%	 (SOR:	
A,	 multiple	 RCTs);	 adding	 metformin	
to	 spironolactone	 improves	 Ferriman-	
Gallwey	 (FG)	 hirsutism	 scores	 an	 addi-
tional	absolute	1.4%	(SOR:	B,	RCT).	Oral	
contraceptive	 pills	 (OCPs)	 are	 12	 times	
more	 likely	 to	 result	 in	 complete	 men-
strual	 regularity	 than	 metformin	 (SOR:	
A,	meta-analysis).	Combining	OCPs	with	
metformin	 improves	 hirsutism	 scores	 by	
8%	over	using	an	OCP	alone	(SOR:	A,	meta-
analysis).	
Statin	medications	don’t	alter	weight,	
hirsutism,	or	menstruation	(SOR:	B,	small	
meta-analysis).
Evidence summary
Women	 with	 PCOS	 who	 are	 not	 seeking	
pregnancy	 commonly	 have	 symptoms	 such	
as	 excessive	 weight,	 hirsutism,	 and	 men-
strual	 irregularities.	 This	 review	 focuses	 on	
interventions	 to	 manage	 those	 symptoms.	
The	 TABLE summarizes	 the	 results	 of	 the	
interventions.
Lifestyle modification improves symptoms; 
no benefit to adding metformin 
A	 Cochrane	 meta-analysis	 of	 6	 RCTs	 with	
164	patients	compared	LSM	(with	diet	and	ex-
ercise)	and	no	or	minimal	intervention.	LSM	re-
duced	weight	more	than	minimal	intervention	
(mean	difference	[MD]=-3.5	kg;	95%	confidence	
interval	[CI],	-4.5	to	-2.0).1	It	also	improved	hir-
sutism,	 assessed	 with	 the	 36-point	 FG	 score,	
where	a	lower	score	corresponds	to	less	hirsut-
ism	(MD=-1.2	points,	95%	CI,	 -2.4	 to	 -0.1).	No	
data	were	available	on	menstrual	regularity.	
A	 double-blind	 RCT	 comparing	 LSM	
alone	 with	 LSM	 plus	metformin	 in	 114	 pa-
tients	 with	 PCOS	 found	 no	 difference	 in	
mean	 weight	 reduction	 (-2-	 to	 -3	 kg,	 data	
from	graph),	ovulation	rate,	or	androgen	lev-
els	at	6	months.2	Six	patients	dropped	out	of	
the	LSM-with-metformin	group,	whereas	no	
patients	dropped	out	of	the	LSM-alone	group.	
Metformin decreases BMI  
more than thiazolidinediones
In	a	meta-analysis	of	10	RCTs	(459	patients)	
comparing	 the	 effects	 of	 metformin	 and	
thiazolidinediones	 (TZDs),	 metformin	 re-
duced	 body	 mass	 index	 (BMI)	 more	 than	
TZDs	 at	 3	 months	 (weighted	 mean	 differ-
ence	[WMD]=-2.5	kg/m2;	95%	CI,	-3.3	to	-.6)	
and	6	months	 (WMD=-0.70	kg/m2;	95%	CI,	
-0.76	to	-0.65).3	
In	 a	 prospective	 cohort	 dose-	
comparison	study,	201	women	with	PCOS	re-
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ceived	either	metformin	1000	mg	or	1500	 to	
1700	 mg	 daily	 for	 6	 months.	 Patients	 were	
asked	 not	 to	 modify	 their	 diet	 or	 exercise	
routines.	 In	 both	 dosage	 groups,	 patients	
lost	weight	from	baseline	(-3	kg;	P<.01),	and	
the	 number	 of	 menstrual	 cycles	 increased	
(0.7	 per	 6	months;	P<.001).4	 No	 clear	 dose-
response	relationship	was	observed.
Spironolactone can  
significantly reduce hirsutism
A	 systematic	 review	 identified	 4	 studies	
(132	 patients)	 of	 antiandrogen	 therapy	 for	
hirsutism	 in	 PCOS.	The	 3	 studies	 that	 used	
the	FG	score	as	an	outcome	all	 showed	sig-
nificant	 reductions	 in	 hirsutism	 after	 6	 to	
12	months	of	treatment	with	spironolactone.5
A	 6-month	 RCT	 of	 198	 patients	 with	
PCOS	 compared	 outcomes	 for	 spironolac-
tone	 (50	mg/d),	metformin	 (1000	mg/d),	 or	
both.	Combined	therapy	was	marginally	bet-
ter	 than	 either	 agent	 alone	 for	 reducing	 the	
FG	 score	 (end	 score	 for	 combined	 therapy	
9.1	vs	9.6	for	spironolactone	and	9.7	for	met-
formin,	an	absolute	difference	for	combined	
therapy	vs	spironolactone	of	-0.5	FG	points	or	
-1.4%;	P<.05).6	
OCPs normalize menstrual cycles  
and reduce hirsutism 
A	 Cochrane	 review	 evaluating	 the	 effects	 of	
OCPs	on	patients	with	PCOS	included	4	RCTs	
(104	patients)	that	compared	OCPs	with	met-
formin	(1500-2000	mg/d)	and	2	RCTs	(70	pa-
tients)	 that	 compared	 the	combination	of	 an	
OCP	and	metformin	with	the	OCP	alone.	Use	
of	 an	OCP	was	much	more	 likely	 to	normal-
ize	 menstrual	 cycling	 than	metformin	 alone	
(2	 trials,	 N=35;	 odds	 ratio	 [OR]=12;	 95%	 CI,	
2.2-100).	Combining	an	OCP	with	metformin	
resulted	 in	 slightly	 better	 FG	 scores	 than	 an	
OCP	 alone	 (1	 trial,	N=40;	WMD=-2.8	 points;	
95%	CI,	-5.4	to	-0.17).7	There	was	no	difference	
in	 the	 final	 BMI	 between	 patients	 taking	 an	
OCP	alone,	metformin	alone,	or	both.
An	RCT	of	35	patients	compared	 the	ef-
fect	on	insulin	levels	of	an	OCP	with	rosigli-
tazone	4	mg/d	and	also	looked	at	menstrual	
cycling	 as	 a	 secondary	 outcome.	The	 study	
found	no	difference	 in	effect	on	 insulin	 lev-
els	 in	 the	 2	 groups.	 All	 patients	 taking	 the	
OCP	 reported	 regular	 menstrual	 cycles	 at	
the	 end	 of	 the	 study	 compared	with	 75%	of	
the	patients	taking	rosiglitazone	(P=.7).8	The	
study	was	underpowered	to	find	a	difference,	
however.
Statins alone don’t affect hirsutism,  
menstruation, or BMI 
A	 Cochrane	 review	 identified	 4	 RCTs	
(244	 women,	 ages	 18-39	 years)	 that	 com-
pared	 a	 statin	 alone	with	 placebo,	 another	
agent,	 or	 another	 agent	 plus	 a	 statin.9	 One	
RCT	of	48	patients	found	that	a	statin	com-
bined	 with	 an	 OCP	 improved	 hirsutism	
compared	 with	 a	 statin	 alone.	 Two	 RCTs	
(85	 patients)	 found	 that	 statins	 didn’t	 lead	
to	 resumption	 of	 regular	menstrual	 cycles.	
Statins	also	didn’t	 alter	BMI	 in	3	 studies	of	
105	patients.
Trials report no adverse effects,  
but VTE may be a concern with OCPs 
A	meta-analysis	evaluated	the	safety	of	met-
formin,	OCPs,	and	antiandrogens		in	22	clini-
cal	trials	with	1335	patients,	primarily	PCOS	
patients.	The	trials	reported	no	cases	of	lactic	
acidosis	 with	 metformin,	 no	 drug-induced	
liver	 injury	 with	 antiandrogens,	 and	 no	 ve-
nous	 thromboembolism	 (VTE)	 with	 OCPs.	
The	 meta-analysis	 authors	 noted,	 however,	
that	 in	 a	 cohort	 trial	 of	 1.6	 million	 Danish	
women	followed	for	15	years,	OCPs	were	as-
sociated	with	a	2-	to	3-fold	increase	in	risk	of	
VTE,	with	higher	risks	 linked	to	higher	ethi-
nyl	estradiol	content.10
Recommendations
A	 2009	 practice	 bulletin	 from	The	 American	
College	of	Obestetrics	and	Gynecology	(ACOG)	
recommends	 OCPs,	 progestin,	 metformin,	
and	 TZDs	 for	 anovulation	 and	 amenorrhea	
in	 patients	with	 PCOS.	OCPs,	 antiandrogens,	
metformin,	eflornithine,	and	mechanical	hair	
removal	 are	 recommended	 for	 hirsutism.	
ACOG	 advocates	 LSM,	 insulin-sensitizing	
agents	(such	as	metformin),	and	statins	to	pre-
vent	cardiovascular	disease	and	diabetes.11		  JFP
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TABLE
Effect	of	various	treatment	options	on	PCOS	symptoms
Study (N) Intervention comparator Weight change hirsutism  
(Ferriman-Gallwey 
score)
menstruation
meta-analysis1
(164)
lifestyle 
modification
No (or minimal) 
intervention
3.5 kg less 
with lifestyle 
modification
3% lower 
with lifestyle 
modification
NA
RcT2 
(114)
lifestyle
modification +
metformin
lifestyle 
modification
No difference NA No difference in ovulation 
rate
meta-analysis3
(459)
metformin TZD BmI 2.5 points 
lower with 
metformin
No difference No difference  
in ovulation rate
cohort4
(201)
metformin
1000 mg/d
metformin
1500-1700 
mg/d
3 kg less than 
baseline (either 
dose)
No difference 1.4 more cycles per year 
than baseline (either dose)
Systematic 
review5 (132)
Spironolactone None NA 8%-22% lower 
than at baseline
NA
RcT6 (198) Spironolactone + 
metformin
Each agent 
alone 
No difference 1.4% lower than 
spironolactone 
alone; 1.6% lower 
than metformin 
alone
1 more cycle per year  
with combined therapy  
(11 vs 10)
meta-analysis7
(35)
ocP +
metformin
ocP No difference 8% lower NA
meta-analysis7
(104)
ocP metformin No difference NA 12 times more likely to 
normalize with ocP
RcT8
(35)
ocP Rosiglitazone No difference NA 100% regularized with 
ocP; 75% regularized  
with TZD 
RcT9 (48) Statin + ocP Statin NA 3.4% lower with 
statin + ocP
NA
BmI, body mass index; NA, not available; ocP, oral contraceptive pill; PcoS, polycystic ovary syndrome; RcT, randomized controlled trial;   
TZD, thiazolidinedione.
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